A Multi-Institutional Analysis of Elderly Patients Undergoing a Liver Resection for Intrahepatic Cholangiocarcinoma by Vitale, A et al.
A Multi-Institutional Analysis of Elderly Patients Undergoing a Liver Resection
for Intrahepatic Cholangiocarcinoma
ALESSANDRO VITALE, MD, PhD,1 GAYA SPOLVERATO, MD,2 FABIO BAGANTE, MD,2 FAIZ GANI, MD,2
IRINEL POPESCU, MD,3 HUGO P. MARQUES, MD,4 LUCA ALDRIGHETTI, MD,5 T. CLARK GAMBLIN, MD,6
SHISHIR K. MAITHEL, MD,7 CHARBEL SANDROUSSI, MD,8 TODD W. BAUER, MD,9 FENG SHEN, MD,10
GEORGE A. POULTSIDES, MD,11 J. WALLIS MARSH, MD,12 AND TIMOTHY M. PAWLIK, MD, MPH, PhD2*
1Unita di Chirurgia Epatobiliare e Trapianto Epatico, Azienda Ospedaliera-Universita di Padova, Padova, Italy
2Johns Hopkins University School of Medicine, Baltimore, Maryland
3Fundeni Clinical Institute, Bucharest, Romania
4Curry Cabral Hospital, Lisbon, Portugal
5Ospedale San Raffaele, Milan, Italy
6Medical College of Wisconsin, Milwaukee, Wisconsin
7Emory University, Atlanta, Georgia
8University of Sydney, Sydney, Australia
9University of Virginia, Charlottesville, Virginia
10Eastern Hepatobiliary Surgery Hospital, Shanghai, China
11Stanford University, Stanford, California
12University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Background: Little is known regarding postoperative outcomes of elderly patients undergoing liver surgery for intrahepatic cholangiocarcinoma
(ICC).
Methods: Five hundred and eighty-four patients undergoing liver resection for ICC between 1990 and 2015 were identiﬁed. Perioperative
morbidity, mortality, overall survival (OS), and disease-free survival (DFS) were compared between elderly (>70 year, n¼ 129) and non-elderly
(70 years, n¼ 455) patients.
Results: Older patients had a higher incidence of complications (elderly vs. non-elderly; 52.7% vs. 42.6%; P¼ 0.03), as well as major
complications (elderly vs. non-elderly; 24.0% vs. 14.9%; P¼ 0.01); 30-day (0.1% vs. 3.3%; P> 0.05), and 90-day mortality (2.3% vs. 5.5%;
P> 0.05) were comparable. Five-year OS and DFSwere comparable between the elderly and non-elderly patients (OS, 13.3% vs. 24.4%; and DFS;
7.3% vs. 12.0%; P> 0.05). On propensity score matching, DFS and OS were also comparable among non-elderly versus elderly patients. Poor
tumor grade was associated with worse DFS among elderly patients (HR¼ 1.6, 95%CI 1.0–2.6; P¼ 0.04), whereas periductal invasion (HR¼ 1.9,
95% CI 1.1–3.5; P¼ 0.03) and nodal disease (HR¼ 2.3, 95% CI 1.3–3.9; P¼ 0.003) were predictive of shorter DFS among non-elderly patients.
Conclusion: Elderly patients undergoing liver surgery for ICC demonstrated an increased risk of perioperative complications, but comparable
long-term DFS and OS compared with younger patients. Rather, tumor characteristics were more predictive of worse long-term outcomes.
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INTRODUCTION
Cholangiocarcinoma accounts for 3% of all gastrointestinal
malignancies and represents the second most common primary liver
tumor [1–6]. In particular, the incidence of intrahepatic
cholangiocarcinoma (ICC) has been steadily increasing with the
incidence in the United States varying from 0.72 to 0.88 per 100,000
[1–4,7]. Of note, the incidence of ICC increases with age, as older
patients demonstrate an incidence that can be almost twofold higher
than younger patients [1–4,7]. Despite recent advances in care, surgery
remains the preferred therapeutic option for patients with ICC,
conferring a 5-year survival between 30% and 35% [8]. Several
clinicopathological factors have been associated with poor
postoperative outcomes among patients undergoing surgery for ICC
including tumor size, presence of multiple tumors, cirrhosis, lymph
node metastasis, and macrovascular invasion [8–11]. Several other
reports have suggested that patient age may also be a potential negative
prognostic factor [9–13].
Older patients often have a higher incidence of medical
comorbidities, worse performance status, as well as decreased
functional reserve that may place them at a particular risk for worse
postoperative outcomes [1]. However, while several studies have
suggested an increased incidence of postoperative complications
among elderly patients undergoing major liver surgery [14–16], other
studies have failed to note an increased risk of liver resection among the
elderly [17–20]. In addition, the impact of elder age on postoperative
outcomes and long-term survival among elderly patients undergoing
liver surgery for ICC, in particular, remains poorly deﬁned. Given this,
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we sought to evaluate the effect of age on postoperative outcomes
among patients undergoing liver surgery for ICC. In particular, we
aimed to deﬁne perioperative outcomes including postoperative
complication and 90-day mortality, as well as disease-free survival
(DFS) and overall survival (OS) among elderly patients (>70 years)
undergoing liver surgery for ICC using a large multi-center
international database.
METHODS
Study Population and Data Collection
Patients undergoing a hepatic resection for histologically conﬁrmed
ICC between 1990 and 2013 were identiﬁed using a multi-institutional
database of 671 patients collected at 12 major hepato-biliary centers in
North America, Europe, Australia and, Asia (Johns Hopkins Hospital,
Baltimore, Maryland; Medical College of Wisconsin, Milwaukee,
Wisconsin; Stanford University, Stanford, California; University of
Virginia, Charlottesville, Virginia; Emory University, Atlanta,
Georgia; University of Pittsburgh, Pittsburgh, Pennsylvania; Fundeni
Clinical Institute of Digestive Disease, Bucharest, Romania; Curry
Cabral Hospital, Lisbon, Portugal; Hopitaux Universitaires De Geneve,
Geneve, Switzerland; Ospedale San Raffaele, Milan, Italy; Royal
Prince Alfred Hospital, University of Sydney, Sydney, Australia; and
Eastern Hepatobiliary Surgery Hospital, Shanghai, China). Patients
who underwent a palliative procedure (n¼ 39) as well as patients who
were diagnosed with metastatic disease (n¼ 48) were excluded from
the analysis. Thus, the ﬁnal study group included 584 ICC patients
undergoing resection with curative intent. The Institutional Review
Board of each participating institution approved the study.
Demographic and clinicopathological data collected for each patient
included age, gender, body mass index (BMI), American Society of
Anesthesiologist (ASA), physical classiﬁcation score, preexisting
comorbidity and, the presence of preoperative cirrhosis or jaundice.
Tumor-speciﬁc characteristics such as tumor size, number of lesions,
tumor grade, lymph node involvement, macroscopic or microscopic
vascular invasion, perineural invasion, as well as direct invasion of
contiguous organs were collected for each patient. Tumor stage was
classiﬁed according to the 7th edition of the American Joint Committee
on Cancer (AJCC) staging system [21]. Operative details collected for
each patient included the type and extent of hepatic resection, receipt of
lymphadenectomy, margin status, operative time, estimated blood
loss (EBL), and receipt of intraoperative blood transfusion. Major
hepatectomy was deﬁned as the resection of three or more liver
segments according to Couinaud’s classiﬁcation [22]. Resectionmargin
and nodal status were described according to the ﬁnal histopathology
report.
The primary outcomes of interest were DFS and OS, both of which
were calculated from the date of surgery. Secondary, postoperative
outcomes included the development of postoperative complications,
length-of-stay (LOS) for the admission in which the surgery was
performed, postoperative mortality within 30 and 90 days following
surgery, 30-day readmission, the receipt of adjuvant chemotherapy or
radiotherapy, and recurrence of disease. Postoperative complications
were classiﬁed according to the Clavien–Dindo classiﬁcation system
whereby grades 1 and 2 complications were categorized as “minor
complications” and grades 3 and 4 complications classiﬁed as “major
complications” [23]. Recurrence was deﬁned as the presence of a
biopsy-proven tumor or an image that was highly suspicious of tumor
recurrence.
Statistical Analysis
Discrete variables were described as medians with interquartile
range (IQR) and compared using theMann–WhitneyU test. Categorical
variables were described as totals and frequencies and compared
using the x2 test or Fisher’s exact test as appropriate. The nearest
neighbor-matching algorithm was used to calculate a propensity
score to create a comparable, matched cohort of patients of elderly
(>70 years), and non-elderly patients (70 years). The propensity score
was calculated using a multivariable logistic regression analysis with
the patient age group (>70 years) as the dependent variable. The
independent variables were factors that were statistically different in the
multivariable survival analysis comparing the two groups (>70 years
vs. 70 years).
DFS and OS time were calculated using the Kaplan–Meier method
and compared between the two patient groups using the log-rank test.
Univariable and multivariable logistic regression analyses were
performed to assess the association of patient and disease
characteristics with DFS and OS within each patient age group.
Variables found to be statistically signiﬁcant on univariable analysis
were included in the multivariable model to assess for potential
associations and confounding. Statistical analyses were performed
using JMP software version 9.0.l (1989–2010 SAS Institute Inc.) and
STATA version 13.1 (StataCorp LP, College Station, TX). All tests
were two-tailed and statistical signiﬁcance was deﬁned as P< 0.05.
RESULTS
Demographic and Clinicopathological Characteristics
A total of 584 patients underwent hepatic resection for ICC between
1990 and 2013 and met inclusion criteria. The median age of the cohort
was 60 years (IQR: 50.8–69.0) and 53.3% (n¼ 311) were male. Over a
ﬁfth of patients were >70 years (n¼ 129, 22.1%) whereas 77.9% of
patients were 70 years (n¼ 455, 77.9%) at the time of diagnosis.
Signiﬁcant differences in baseline characteristics were noted between
elderly patients (>70 years) and younger patients (70 years). Patients
>70 years old who underwent surgery were proportionally less likely to
present with a bi-lobar tumor (non-elderly vs. elderly; 34.3% vs. 25.6%,
P¼ 0.038). Similarly, major vascular invasion was also more common
among younger patients (non-elderly vs. elderly; 14.9% vs. 7.8%,
P¼ 0.039, Table I).
Postoperative Complications, LOS, 30- and 90-Day Mortality,
and Adjuvant Therapies
Among the unmatched cohort of patients, LOS was comparable
between non-elderly and elderly patients (median LOS: non-elderly vs.
elderly; 10 days [IQR: 6–15] vs. 8 days [IQR: 6–14], P¼ 0.115). Of
note, elderly patients were more likely to develop a postoperative
complication compared with non-elderly patients (non-elderly vs.
elderly; 42.6% vs. 52.7%, P¼ 0.027). Additionally, elderly patients
were also proportionally more likely to develop a major complication
deﬁned as Clavien–Dindo grade2 (non-elderly vs. elderly; 14.9% vs.
24.0%,P¼ 0.0013), as well as be readmitted within 30-day of discharge
(non-elderly vs. elderly; 11.2% vs. 16.3%, P¼ 0.046). Postoperative
mortality within 30- and 90-days was similar between the two groups
(both P> 0.05). Compared with older patients, younger patients were
more likely to receive adjuvant chemotherapy (young vs. elderly;
55.4% vs. 37.2%, P< 0.001, Table IIa).
To minimize potential confounding due to case mix, a propensity-
score matched cohort of comparable patients was created including 129
patients aged70 years and 129 patients>70 years. Of note, among the
cohort of matched patients, LOS, 30-day readmission, and
postoperative mortality were similar between the two patient groups
(all P> 0.05, Table IIb). On matched analysis, elderly patients were
proportionally more likely to develop a major postoperative
complication compared with non-elderly patients (non-elderly vs.
elderly; 14.0% vs. 24.0%, P¼ 0.028). In contrast, elderly patients were
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less likely to receive both adjuvant chemo- and radiation therapy
(chemotherapy: non-elderly vs. elderly; 49.6% vs. 37.2%, P¼ 0.028,
radiation therapy: non-elderly vs. elderly; 23.3% vs. 6.9%, P< 0.001,
Table IIb).
Disease Free and Overall Survival
The median follow-up for the unmatched cohort was 50.6 months
(IQR: 31.2–91.9) while the median follow-up was 43.4 months (IQR:
TABLE I. Clinical and Pathologic Features of Unmatched Patients (n¼ 584)
Characteristic Age 70 years (n¼ 455) Age >70 years (n¼ 129) P-value
Age, year, median (IQR) 55.9 (48.6–63.0) 74.0 (71.2–77.3) <0.0001
Female 211 (46.4%) 62 (48.1%) 0.7647
Non-Caucasian race 88 (19.3%) 8 (6.2%) 0.0002
Cirrhosis 42 (9.2%) 16 (12.4%) 0.3167
ASA class>2 290 (63.7%) 86 (66.7%) 0.6028
Tumor size, cm, median (IQR) 7.0 (5.0–9.4) 6.0 (4.5–9.0) 0.1051
Multiple lesions 143 (31.4%) 43 (33.3%) 0.6703
Bi-lobar tumor 156 (34.3%) 33 (25.6%) 0.0379
CA 19-9, units/ml, median (IQR) 145.4 (23.6–784.0) 93.4 (7.5–514.9) 0.3840
Vascular invasion (major or minor) 155 (34.1%) 39 (30.2%) 0.4591
Major vascular invasion 68 (14.9%) 10 (7.8%) 0.0393
Minor vascular invasion 132 (29.0%) 37 (28.7%) 1.000
Biliary invasion 68 (14.9%) 16 (12.4%) 0.5698
Poor tumor grade 121 (26.6%) 31 (24.0%) 0.6494
Perineural invasion 87 (19.1%) 32 (24.8%) 0.0997
Direct invasion of contiguous organs 52 (11.4%) 10 (7.8%) 0.1498
Periductal invasion 60 (13.2%) 12 (9.3%) 0.1503
Nodal status 0.4496
N0 132 (29.0%) 38 (29.5%)
N1 93 (20.4%) 25 (19.4%)
Nx 230 (50.6%) 66 (51.2%)
AJCC T stage 0.5497
T1 187 (41.1%) 54 (41.9%)
T2a 71 (15.6%) 21 (16.3%)
T2b 105 (23.1%) 34 (26.4%)
T3 32 (7.0%) 8 (6.2%)
T4 60 (13.2%) 12 (9.3%)
AJCCa 0.7672
I 218 (37.4%) 45 (34.9%)
II 179 (30.6%) 45 (34.9%)
III 25 (4.3%) 6 (4.7%)
IVab 162 (27.7%) 33 (25.6%)
R1 margin 83 (18.2%) 27 (20.9%) 0.2838
Major surgical resection (3 segments) 317 (69.7%) 91 (70.5%) 0.4706
Intra-operative blood transfusion 170 (37.4%) 44 (34.1%) 0.2844
Intra-operative blood loss, ml, median (IQR) 500 (250–900) 550 (400–1075) 0.1042
Operative time, min, median (IQR) 230 (180–315) 279 (180–360) 0.1021
aAJCC stage IVa (T4 N0 M0 or any T N1 M0) were included, whereas stage IVb (any T any N M1) were excluded from the study cohort.
bIncludes tumors with periductal-inﬁltrating or mixed mass-forming and periductal-inﬁltrating growth pattern.
TABLE II. (a) Postoperative Outcomes in Unmatched Cohort; (b) Postoperative Outcomes in Matched Cohort
a
Variables Age  70 years (n¼ 455) Age > 70 years (n¼ 129) P-value
Length of stay, days, median (IQR) 10 (6.0–15.0) 8 (6.0–14.0) 0.1145
Any complication 194 (42.6%) 68 (52.7%) 0.0270
Clavien score >2 68 (14.9%) 31 (24.0%) 0.0126
Readmission 51 (11.2%) 21 (16.3%) 0.0455
Adjuvant chemotherapy 252 (55.4%) 48 (37.2%) 0.0002
Adjuvant radiotherapy 57 (12.5%) 9 (6.9%) 0.0500
30-day mortality 15 (3.3%) 1 (0.1%) 0.0988
90-day mortality 25 (5.5%) 3 (2.3%) 0.0994
b
Variables Age  70 years (n¼ 129) Age > 70 years (n¼ 129) P-value
Length of stay, days, median (IQR) 9 (6.0–15.5) 8 (6.0–14.0) 0.3096
Any complication 54 (41.9%) 68 (52.7%) 0.0524
Clavien score >2 18 (14.0%) 31 (24.0%) 0.0280
Readmission 15 (11.5%) 21 (16.3%) 0.0567
Adjuvant chemotherapy 64 (49.6%) 48 (37.2%) 0.0297
Adjuvant radiotherapy 30 (23.3%) 9 (6.9%) 0.0002
30-day mortality 6 (4.7%) 1 (0.1%) 0.0599
90-day mortality 7 (5.4%) 3 (2.3%) 0.1670
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25.6–81.4) for the propensity-matched cohort. For the entire unmatched
cohort, the 1-, 3-, and 5-year DFS was 43.6%, 17.6% and 11.3%,
respectively, and the 1-, 3-, and 5-year OS was 75.4%, 37.4%, and
22.5%, respectively. On unadjusted analyses, there were no differences
in DFS or OS noted between non-elderly and elderly patients: the
median DFS among elderly patients was 11.6 months (IQR: 6.4–25.3)
versus 9.2 months (IQR: 4.6–27.0) among non-elderly patients
(P¼ 0.470, Fig. 1); the median OS was 25.3 months (12.6–40.6)
versus 27.5 months (IQR: 11.8–57.3), respectively (P¼ 0.286, Fig. 1).
On propensity score matching, DFS and OS were also comparable
among non-elderly versus elderly patients. Speciﬁcally, the median
DFS among non-elderly patients was 9.1 months (IQR: 5.2–26.0;
P¼ 0.42, Fig. 2), while median OS in the same subgroup was 27.3
months (IQR: 12.1–63.2; P¼–0.357, Fig. 2).
Multivariable logistic regression analysis was performed to assess
patient and disease factors predictive of OS andDFS among non-elderly
and elderly patients. Of note, tumor grade (HR 1.7, 95% CI 1.0–2.9;
P¼ 0.04) and periductal invasion (HR 2.5, 95% CI 1.1–5.3; P¼ 0.03)
were predictive of a poor OS among elderly patients, while CA-
19.9> 125 U/ml (HR 1.8, 95%CI 1.1–2.9; P¼ 0.02), vascular invasion
(HR 2.3, 95% CI 1.3–4.1; P¼ 0.007), poor tumor grade (HR 1.9, 95%
CI 1.1–3.5; P¼ 0.03), periductal invasion (HR 4.2, 95% CI 1.9–9.1;
P< 0.001), and receipt of adjuvant radiotherapy (HR 2.0, 95% CI 1.1–
3.4; P¼ 0.01) were more important predictors of worse OS among non-
elderly patients (Table III). Poor tumor grade was the only
clinicopathological characteristic associated with a worse DFS
among elderly patients (HR 1.6, 95% CI 1.0–2.6; P¼ 0.04), while
periductal invasion (HR 1.9, 95%CI 1.1–3.5; P¼ 0.03) as well as nodal
disease (HR 2.3, 95% CI 1.3–3.9; P¼ 0.003) were predictive of a
shorter DFS among non-elderly patients (Table III). To further assess
the relationship between age, nodal disease and DFS, patients were
stratiﬁed by node status and DFS was stratiﬁed by non-elderly versus
elderly. Interestingly, among patients with nodal metastasis, DFS was
better among elderly patients when compared with DFS among
non-elderly patients (P¼ 0.04, Fig. 3A); in contrast, DFS was similar
among non-elderly and elderly patients who had no lymph node
metastasis (Fig. 3B).
DISCUSSION
There has been a marked increase in the incidence of ICC, making
it the second most common primary liver cancer [1–6]. As surgical
management is the gold standard of care for patients presenting with
ICC, and given that the population is aging, it is expected that the
number of patients undergoing a hepatic resection for ICC will increase
[1–6]. Although several studies have examined hepatic resection among
Fig. 1. Kaplan–Meier curves comparing: (a) overall survival and (b) disease-free survival among elderly versus non-elderly in the unmatched
cohort.
Fig. 2. Kaplan–Meier curves comparing: (a) overall survival and (b) ﬁsease-free survival among elderly versus non-elderly in the propensity-
score matched cohort.
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elderly patients, the results were disparate and no previous study
speciﬁcally examined elderly patients undergoing surgery for ICC. As
such, we sought to use a large multinational cohort of 584 patients to
assess postoperative outcomes among elderly patients undergoing
hepatic resection for ICC. The current study is important because it
noted that although elderly patients were more likely to develop severe
postoperative complications, and were less likely to receive adjuvant
therapy, no differences in DFS or OSwere noted between elderly versus
non-elderly patients. Rather than age, disease characteristics such as
tumor invasion and nodal status were more predictive of long-term
outcome among all patients.
Given the increasing aged surgical population, it is not surprisingly
that the number of elderly patients undergoing hepatic resection for
treatment of liver cancer is progressively increasing [24]. Although
surgical resection remains themainstay forpotential cure for liver tumors,
it is unclear whether the beneﬁts of surgery are conferred to the elderly
patient. Previous reports have identiﬁed elderly patients are a potential
high-risk group following liver surgery due to greater preexisting
comorbidity, poly-pharmacy, and decreased physiological reserve [1,2].
Consistent with these ﬁndings, the current study noted that, compared
with non-elderly patients, elderly patients were more likely to develop
a severe postoperative complication. Interestingly, this difference was
also noted after patients were matched on several patient and disease
characteristics. These data suggest that age may be a potential
independent risk factor for developing postoperative complications. In
a recent meta-analysis, Phan et al. reported that elderly patients were
more likely to develop major postoperative complications including
pneumonia, heart failure, surgical site infections, and renal failure
compared with younger patients [25]. However, the majority of previous
studies haveonly includeddata onpostoperative outcomes among elderly
patients undergoing liver surgery for hepatocellular carcinoma or
colorectal liver metastasis. As such, to our knowledge, the current
study represents the ﬁrst study to assess postoperative outcomes among
elderly patients undergoing liver surgery for the management of ICC.
TABLE III. Multivariate Overall and Disease Free Survival Analyses in Study and Control Groups After Propensity Score Analysis
Variables Age 70 years HR (95% CI), P-value Age >70 years HR (95% CI), P-value
Overall Survival
Non Caucasian race 0.85 (0.37–2.21), 0.7201 0.33 (0.16–0.82), 0.0194
Size >5 cm 1.58 (0.91–2.81), 0.1063 1.48 (0.86–2.57), 0.1554
CA 19-9 >125U/ml 1.80 (1.11–2.92), 0.0162 1.16 (0.72–1.86), 0.5465
Vascular invasion (major or minor) 2.28 (1.26-–4.11), 0.0068 1.06 (0.58–1.89), 0.8362
Biliary invasion 0.55 (0.24–1.15), 0.1127 0.53 (0.24–1.11), 0.0913
Poor tumor grade 1.95 (1.08–3.47), 0.0279 1.75 (1.01–2.95), 0.0457
Direct invasion of contiguous organs 1.50 (0.51–3.94), 0.4435 0.99 (0.39–2.14), 0.9722
Periductal invasiona 4.22 (1.90–9.06), 0.0005 2.46 (1.07–5.30), 0.0345
Positive nodal status 1.59 (0.88–2.77), 0.1235 1.25 (0.68–2.20), 0.4645
Major surgical resection 1.01 (0.55–1.90), 0.9796 1.03 (0.60–1.80), 0.9167
Adjuvant radiotherapy 2.01 (1.15–3.38), 0.0148 2.18 (0.88–4.67), 0.0886
Disease Free Survival
Non Caucasian race 0.43 (0.20–1.03), 0.0590 0.38 (0.18–0.93), 0.0364
Size >5 cm 1.22 (0.77–1.96), 0.4004 1.43 (0.88–2.36), 0.1498
Multiple lesions 1.23 (0.80–1.88), 0.3495 1.00 (0.64–1.52), 0.9874
Vascular invasion (major or minor) 1.44 (0.86–2.38), 0.1662 1.19 (0.71–1.99), 0.5049
Poor tumor grade 1.87 (1.12–3.05), 0.0170 1.65 (1.02–2.62), 0.0427
Direct invasion of contiguous organs 1.43 (0.59–3.09), 0.4079 1.08 (0.49–2.12), 0.8273
Periductal invasiona 1.97 (1.07–3.51), 0.0301 1.65 (0.80–3.19), 0.1690
Positive nodal status 2.31 (1.34–3.87), 0.0031 1.14 (0.65–1.94), 0.6407
Major surgical resection 1.15 (0.69–1.94), 0.6060 1.25 (0.78–2.06), 0.3598
Adjuvant chemotherapy 0.81 (0.52–1.24), 0.3305 1.52 (0.98–2.36), 0.0640
Adjuvant radiotherapy 1.62 (1.01–2.54), 0.0465 1.10 (0.45–2.28), 0.8188
aIncludes tumors with periductal-inﬁltrating or mixed mass-forming and periductal-inﬁltrating growth pattern.
Fig. 3. Kaplan–Meier curves comparing disease-free survival among the elderly versus non-elderly in the propensity-score matched cohort
among patients with (a) and without lymph node metastasis (b).
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Decisions to treat elderly patients with cancer are multifaceted
and complex. Speciﬁcally, given the high postoperative morbidity
associated with oncological surgery, elderly patients represent a unique
challenge for healthcare providers. Similarly, several previous reports
have demonstrated that treatment decisions can be largely driven by
patient age with elderly patients being less likely to receive surgical
or medical treatments compared with younger patients who have
comparable disease [26–28]. For example, in a large survey of primary
care providers, age at diagnosis was independently associated with the
decision not to refer patients with advanced cancer for further treatment
[26]. In a separate study, Guadagnoli et al. reported that up to 50% of
elderly patients presenting with breast cancer were “undertreated”
despite evidence suggesting that these patients would have beneﬁted
from treatment [29]. In the current study, using a matched cohort of
elderly and non-elderly patients, we noted that elderly patients were less
likely to receive adjuvant treatment in the form of chemotherapy or
radiation therapy compared with non-elderly patients presenting with
similar disease. Taken together, the ﬁndings of the current study as well
as past reports, strongly suggest that patient age may inﬂuence a
provider’s choice to offer peri-operative adjuvant therapy to elderly
patients. The reason for this is undoubtedly multi-factorial and may be
related to the higher incidence of complications in the elderly or
physician concern that therapy will not be as well tolerated in older
patients. Although the role of adjuvant therapy for ICC is poorly
deﬁned, it is interesting that elderly patients were less likely to undergo
adjuvant therapy, yet had similar DFS and OS in the matched cohort.
Moreover, adjuvant chemotherapy had a negative prognostic impact in
elderly patients and adjuvant radiotherapy decreased survival in non-
elderly patients. These ﬁndings were undoubtedly inﬂuenced by
selection bias (i.e., patients with more aggressive tumors received
adjuvant therapy). In addition, these ﬁndings corroborate the modest
effect that adjuvant therapy likely has on the oncological outcome of
patients undergoing liver resection for ICC. In the future, more robust
clinical tools will need to be employ to more accurately identify, which
elderly patients would beneﬁt the most from adjuvant therapies.
Another interesting ﬁnding of the current study was that both OS and
DFS were comparable among elderly and non-elderly patients. In
contrast, tumor characteristics were more predictive of worse survival.
Interestingly, there were several factors that seemed to have a
differential prognostic effect based on patient age. Speciﬁcally,
among younger patients CA 19-9 serum level, vascular invasion,
poor tumor grade, periductal invasion, and adjuvant radiotherapy were
independent predictors of OS, while only periductal invasion and tumor
grade were predictive of a worse OS among the elderly. Similarly,
periductal invasion and nodal disease were associated with poor DFS
among younger patients, while only poor tumor differentiation was
associated with a worse DFS among the elderly. Consistent with the
ﬁndings of the current study, Mavros et al. in a systematic review
identiﬁed poor tumor differentiation, nodal disease, and vascular
invasion as most predictive of survival among patients undergoing
surgery for ICC [3]. In a separate study, Menon and colleagues reported
that, while agewas not independently associatedwithworse OS or DFS,
other disease characteristics such as the number of tumors as well
preexisting comorbidities were predictive of survival [1]. Taken
together these ﬁndings suggest that hepatic surgery should not be denied
to elderly patients. While the risk of perioperative morbidity may be
higher in the elderly, elderly patients can enjoy comparable long-term
outcomes compared with non-elderly patients. Rather, the collective
data suggest that tumor speciﬁc factors, and not age itself determines
prognosis.
The current study has several limitations. Given the retrospective
nature of the study, no data on performance status was available.
Although the ASA score was used as a surrogate for performance status/
comorbidity, it is possible that potential confounding due to case mix
may have been unaccounted for. In particular the lack of data on
comorbidities is a limitation of the study, although the ASA score was
available in the majority of patients. Additionally, as data were
collected from multiple institutions, the pre-, intra-, and postoperative
management across participating institutions may have varied.
However, the use of data collected from multiple institutions allowed
for a larger sample size and greater generalizability of the results.
Despite this, the sample size for the matched cohorts was relatively
small (n¼ 129), which in turn limited the statistical power of some
analyses. Lastly, despite the use of a propensity score matching
algorithm, it is possible that there was some selection bias in the patient
groups that remained unaccounted for due to the retrospective nature of
the database.
In conclusion, elderly patients undergoing liver surgery for ICC
demonstrated an increased risk of perioperative complications, but
comparable long-term DFS and OS compared with younger patients.
Rather, tumor characteristics, such as lymph node metastasis and
periductal invasion, were more predictive of worse DFS. As such, age
alone should not be a contraindication for hepatic resection and surgery
should be considered in all cases, where disease is amenable to
extirpation. In the future, more robust tools will be necessary to identify
those elderly patients at greatest risk for poor postoperative outcomes
following hepatic surgery for ICC.
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